Prelude Capital Management’s Roivant Sciences ROIV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.86M | Sell |
164,780
-99,820
| -38% | -$1.12M | 0.18% | 143 |
|
|
2025
Q1 | $2.67M | Buy |
264,600
+19,660
| +8% | +$198K | 0.2% | 79 |
|
|
2024
Q4 | $2.9M | Sell |
244,940
-29,230
| -11% | -$346K | 0.18% | 91 |
|
|
2024
Q3 | $3.16M | Buy |
274,170
+11,892
| +5% | +$137K | 0.19% | 105 |
|
|
2024
Q2 | $2.77M | Sell |
262,278
-4,478
| -2% | -$47.3K | 0.19% | 120 |
|
|
2024
Q1 | $2.81M | Buy |
266,756
+248,555
| +1,366% | +$2.62M | 0.15% | 134 |
|
|
2023
Q4 | $204K | Sell |
18,201
-4,079
| -18% | -$45.8K | 0.01% | 810 |
|
|
2023
Q3 | $260K | Sell |
22,280
-27,020
| -55% | -$316K | 0.02% | 630 |
|
|
2023
Q2 | $497K | Buy |
49,300
+8,500
| +21% | +$85.7K | 0.03% | 396 |
|
|
2023
Q1 | $301K | Buy |
40,800
+19,700
| +93% | +$145K | 0.02% | 568 |
|
|
2022
Q4 | $169K | Buy |
+21,100
| New | +$169K | 0.01% | 872 |
|